TME PHARMA ANNOUNCES THE END OF THE CONVERTIBLE DEBT PROGRAM WITH THE SUCCESSFUL €1.48 MILLION FINANCING INTENDED FOR BUYBACK OF ALL OUTSTANDING CONVERTIBLE DEBT

  • €1.48 million private placement secured from a group of new investors
  • Buyback will mark the end of TME Pharma's convertible bond program

Proceeds to be used for buyback of all remaining outstanding convertible debt enhancing TME Pharma’s profile for investors prior to imminent FDA regulatory milestones 

full press release in PDF: EN

Back